"Being able to quickly update protein vaccines against fast-emerging viral mutations has the potential to be a gamechanger when faced with future COVID-19 variants or another evolving threat." CEPI is giving Boost Biopharma a $5 million cash injection to advance its cutting-edge rapid antigen design process. This novel approach has the potential to quickly create new vaccines against troublesome viruses. Boost’s vaccines are made with protein antigens—molecules that mimic a part of a virus which our bodies then recognize and respond to—in order to provide protective immunity. Accelerating the development of protein vaccines could enable faster responses to future emerging outbreaks, in support of the #100DaysMission ▶ https://lnkd.in/e93wzBAU
CEPI (Coalition for Epidemic Preparedness Innovations)
Forskningstjenester
We want to stop future epidemics by developing new vaccines for a safer world.
Om oss
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines against future epidemics. Prior to COVID-19, CEPI’s work focused on developing vaccines against the Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus. It has over 20 vaccine candidates against these pathogens in development. CEPI has also invested in new platform technologies for rapid vaccine development against unknown pathogens (Disease X). During the COVID-19 pandemic, CEPI initiated multiple programmes to develop vaccines against SARS-CoV-2 and its variants with a focus on speed, scale, and access. These programmes leverage the rapid response platforms developed by CEPI’s partners prior to the emergence of COVID-19, as well as new collaborations. The aim is to advance clinical development of a diverse portfolio of safe and effective COVID-19 candidates and to enable fair allocation of these vaccines worldwide through COVAX. CEPI’s 5-year plan lays out a $3.5 billion roadmap to compress vaccine development timelines to 100 days, develop a broadly protective vaccine against COVID-19 and other Betacoronaviruses, and create a “library” of vaccine candidates for use against known and unknown pathogens. The plan is available at www.endpandemics.cepi.net
- Nettsted
-
http://www.cepi.net
Ekstern lenke til CEPI (Coalition for Epidemic Preparedness Innovations)
- Bransje
- Forskningstjenester
- Bedriftsstørrelse
- 51–200 ansatte
- Hovedkontor
- Oslo
- Type
- Ideell organisasjon
- Grunnlagt
- 2017
- Spesialiteter
- Epidemic Preparedness, Vaccine Development, Vaccine, Health, Science
Beliggenheter
-
Primær
Skøyen Atrium, Askekroken 11
Oslo, 0277, NO
-
215 Euston Road
London, England, GB
-
1901 Pennsylvania Ave NW
Washington, District of Columbia 20006, US
Ansatte i CEPI (Coalition for Epidemic Preparedness Innovations)
Oppdateringer
-
The potential human epidemic threat posed by the outbreak of H5N1 bird flu among dairy cattle in the United States is “increasing daily”, says Dr Rick Bright. For this new article, Kate Kelland spoke with the global flu expert at #GPPS2024 to get an understanding of just how concerning the current H5N1 outbreak is and why we need to take steps to get ahead of it. The article highlights that while H5N1 has so far shown little ability to spread person-to-person, there are “a lot of people that work daily in constant interaction with these animals”, so “the chance for infection via spillover into people is a daily risk. And it’s increasing.” Read the full article to learn more, including why CEPI is taking a “no-regret” approach to the current outbreak ➡️ https://lnkd.in/eFQcpxsy
-
📰 A special edition of CEPI Updates & Insights has just landed, stacked with insights from the recent Global Pandemic Preparedness Summit 2024. Delve into this month's newsletter to learn more about the key messages that emerged from the two-day Summit in Rio de Janeiro, CEPI's new manufacturing partnership with one of Latin America's largest vaccine manufacturers, as well as access to the latest available recordings of the Summit. Beyond #GPPS2024, discover more about CEPI's latest investments, including funding to advance a monoclonal antibody for Nipah virus, expanding potential use of existing Chikungunya and mpox vaccines, and plenty, plenty more.
-
With our partners World Health Organization, we’re calling on researchers and Governments to strengthen and accelerate global research to prepare for the next pandemic. WHO’s new report, issued at the Global Pandemic Preparedness Summit 2024, urges the world to follow a broad-based approach that encompasses entire families of pathogens in their research as well as focusing on individual pathogens. This approach suggests using prototype pathogens as guides or pathfinders to help develop the knowledge base on entire pathogen families. Having broadly applicable knowledge, tools and countermeasures could enable us to rapidly adapt and respond to emerging threats. As our CEO Richard Hatchett explains: “This framework will help steer and coordinate research into entire pathogen families, a strategy that aims to bolster the world’s ability to swiftly respond to unforeseen variants, emerging pathogens, zoonotic spillover, and unknown threats referred to as pathogen X.” #GPPS2024 Find out more: https://lnkd.in/gCYiZk-K
-
Tthe Regionalized Vaccine Manufacturing Collaborative launched its new strategy during the recent Global Pandemic Preparedness Summit 2024. “We’ve never had a better chance to advance vaccine equity and health security for all than now, and through our 2024-27 strategy we’re committed to working with all partners to create regional vaccine manufacturing as a core element to deliver this, said RVMC’s Managing Director Frederik Kristensen. RVMC, an initiative supported by CEPI, the World Economic Forum and The National Academies of Sciences, Engineering, and Medicine, is uniquely suited to provide stakeholders with the support they need, being the only organization fully dedicated to the vaccine regionalization agenda, and intentionally positioned between regions and between global and regional bodies. #GPPS2024 #RVMC https://lnkd.in/dZ85gG_s
Creating sustainable pathways to regional vaccine manufacturing | CEPI
cepi.net
-
That’s a wrap on the Global Pandemic Preparedness Summit 2024 👏 The two-day summit, co-hosted by Ministério da Saúde, FIOCRUZ - Fundação Oswaldo Cruz, and CEPI featured more than 20 sessions and 80 speakers, advancing critical conversations that will help better prepare the world for future pandemic threats. These conversations centred around efforts to ramp up regional manufacturing and enable equitable access to health tools and countermeasures in response to epidemic and pandemic threats within 100 days. As well as examining how climate change is heightening pandemic risk, recent developments with the Pandemic Agreement negotiations and more. During the closing remarks Fiocruz president, Mario Moreira, also announced the Rio Declaration, calling for greater collaboration between the Global North & Global South to overcome disparities in access to health tools & countermeasures in LMICs. More: bit.ly/3LHzHvU A huge thanks to all the organizing partners, FIND, Unitaid, International Pandemic Preparedness Secretariat, Pan American Health Organization, the WHO Hub, and World Health Organization, as well as to the speakers and guests, for contributing to such an energising programme. A final report integrating all the Summit proceedings and recommendations from #GPPS2024 will be published in the coming weeks – stay tuned! In the meantime, check out the end of Summit release to explore more key highlights, or check out #GPPS2024. https://lnkd.in/eKA_yPXT
Global Summit reinvigorates efforts to prepare for future pandemics | CEPI
cepi.net
-
CEPI (Coalition for Epidemic Preparedness Innovations) la ut dette på nytt
A segunda edição da Cúpula Global de Preparação para Pandemias (GPPS, na sigla em inglês) teve início hoje (29/7). O evento reúne, em dois dias, especialistas em P&D e fabricação, autoridades governamentais, representantes da sociedade civil e líderes da indústria e da comunidade global de saúde para encontrar, em conjunto, soluções para enfrentar futuros surtos e pandemias de forma mais rápida e equitativa para todos os países. A Cúpula é organizada pela Coalizão para Inovações em Preparação para Epidemias (CEPI (Coalition for Epidemic Preparedness Innovations), a Fiocruz e o Ministério da Saúde. Pela manhã, Bio-Manguinhos / Fiocruz se tornou o mais novo parceiro a se juntar à rede da Cepi de fabricantes de vacinas no Sul Global. A rede trabalha para apoiar respostas rápidas e equitativas a futuras ameaças de doenças infecciosas emergentes. A inclusão da Fiocruz impulsionará significativamente os esforços de produção de vacinas na região da América Latina e do Caribe, aumentando a capacidade para produzir imunizantes em resposta a ameaças epidêmicas e pandêmicas. A Coordenação de Comunicação Social da Fiocruz montou um espaço para discussões sobre os desafios na preparação para pandemias dos países do Sul Global. Diversos especialistas estão sendo entrevistados para uma série que estará no canal da Fundação. #fiocruz #gpps2024 #pandemias
-
+ 3
-
Great to see these very promising results from a Phase 1 clinical trial of a vaccine candidate against Rift Valley Fever demonstrating a high safety profile and excellent tolerability, eliciting robust immune responses. This is an important step towards a safe and effective RVF vaccine for human use. The trial was conducted in Belgium by Wageningen Bioveterinary Research funded by CEPI with support form #Horizon2020 and is recently published in The Lancet. Rift Valley Fever is a potential deadly viral disease and has been a CEPI priority since 2019. It most commonly affects domesticated animals, such as cattle, sheep, goats, and camels. However, Rift Valley Fever can also cause infection and outbreaks in people, symptoms of which range from mild disease to a severe haemorrhagic form that can have up to 50% fatality. Read more about Rift Valley Fever on our website 👇 https://lnkd.in/dhbF_swg
💉🚶♂️ The live-attenuated Rift Valley fever vaccine called ‘hRVFV-4s’ was shown safe in 75 participants in a Phase 1 clinical trial performed in Belgium. The outcomes of the trial were published in The Lancet Infectious Diseases. “We are pleased to see that the participants in this first human trial didn’t experience any major adverse events following vaccination and a promising immune response was induced”, says Paul Wichgers Schreur, researcher at Wageningen Bioveterinary Research and leading the LARISSA consortium that develops the vaccine. Rift Valley fever virus, a pathogen to ruminants, camelids, and humans, is an emerging mosquito-borne bunyavirus currently endemic to Africa and the Arabian Peninsula. Although animals are primarily infected via mosquito bites, humans mainly become infected following contact with infected tissues or fluids of infected animals. “There is an urgent need for adequate countermeasures, especially for humans, because effective therapeutics or vaccines are not yet available”, explains Paul. WBVR is the leading partner the LARISSA consortium that develops the live-attenuated hRVFV-4s vaccine beyond initial proof of concept. The consortium is funded by the CEPI (Coalition for Epidemic Preparedness Innovations) with support from the EU Horizon 2020 programme. In this first human trial The hRVFV-4s vaccine showed a favourable safety profile, good tolerability, and induced a strong humoral and cellular immune response in healthy individuals. Given these promising outcomes, further evaluation of the vaccine in populations at highest risk for Rift Valley fever is warranted. 👉 More information on this trial is available in the scientific paper published in The Lancet Infectious Diseases: https://lnkd.in/egebfKkQ #OneHealth #research #vaccinedevelopment
-
Day 1 of the Global Pandemic Preparedness Summit 2024 is complete. Thank you to all our speakers and guests today who contributed to these vital discussions. Lots of fascinating exchanges today looking at: 🔵 Opportunities to strengthen disease surveillance 🔵 How close we are to realizing the #100DaysMission 🔵 Enabling equitable access through regional production 🔵 How we can prepare for a zoonotic flu pandemic And plenty more. One clear theme has emerged: we’ve made significant progress in pandemic readiness and preparedness, but there is a long way to go before the world can confidently respond quickly and equitably to a pandemic threat. #GPPS2024 is a key forum for raising these issues and having discussions that can carve a clear path forward, helping to reinvigorate momentum behind global pandemic preparedness so that we can take the threat of pandemics off the table once and for all. Join us tomorrow for Day 2 of #GPPS2024. You can listen to panel sessions in real time by joining the live-stream link: bit.ly/3SaGm5r
-
A new clinical trial due to launch in the Democratic Republic of Congo and other countries in Africa will assess whether an mpox vaccine can protect people against the disease after they have come into contact with the potentially deadly infection: https://lnkd.in/dsCNkREY Funded by CEPI and the Canadian Institutes of Health Research | Instituts de recherche en santé du Canada, the ‘SMART’ trial aims to find out if post-exposure vaccination of Bavarian Nordic’s MVA-BN® mpox vaccine could reduce the risk of secondary mpox cases, or, if a person contracts mpox, could reduce their severity of illness. As H.E. Dr Jean Kaseya, Director General of Africa CDC, shared: “The SMART trial demonstrates the power of scientific collaboration, which could provide important data on the potential role of post-exposure mpox vaccinations.” Evidence generated could be crucial in shaping mpox vaccination strategies to help tackle the escalating outbreak of mpox in the DRC and neighbouring countries. Over 11,000 cases and 443 deaths have been reported in the DRC so far this year, with children accounting for the majority of infections and deaths. The announcement was made today at the launch of the Global Pandemic Preparedness Summit 2024, co-hosted by CEPI, Ministério da Saúde and FIOCRUZ - Fundação Oswaldo Cruz in Rio de Janeiro, Brazil: cepi.net/gpps
New clinical trial will assess if mpox vaccination works after virus exposure | CEPI
cepi.net